SMS Pharmaceuticals Limited AI Stock Analysis
Want to see IN:SMSPHARMA full AI Analyst Report?
SMS Pharmaceuticals Limited (SMSPHARMA) AI Stock Analysis
SMS Pharmaceuticals Limited
(NSE:SMSPHARMA)
SMS Pharmaceuticals secures a solid overall score driven by highly bullish technical momentum, surging profitability, and a deleveraging balance sheet. The company is in a strong expansion phase, but investors should monitor its premium valuation multiple and persistently negative free cash flow, which remain the primary balancing risks.
SMS Pharmaceuticals Limited (SMSPHARMA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 44.70B
- Dividend Yield
- 0.08%
- Average Volume (3M)
- 39.91K
- Price to Earnings (P/E)
- 38.0
- Beta (1Y)
- 1.08
- Revenue Growth
- 12.96%
- EPS Growth
- 32.16%
- Country
- India
- Employees
- 1,617
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - General
SMS Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of AP...
SMS Pharmaceuticals Limited Financial Statement Overview
Summary
Robust revenue and profit growth paired with a deleveraging balance sheet are major strengths, though persistently negative free cash flow driven by heavy capital reinvestment poses a liquidity risk.
Income Statement
88Very PositiveBalance Sheet
85Very PositiveCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.73B | 8.87B | 7.83B | 7.09B | 5.22B | 5.15B |
| Gross Profit | 2.73B | 1.75B | 1.45B | 2.11B | 1.29B | 1.81B |
| EBITDA | 1.97B | 1.71B | 1.45B | 1.18B | 593.89M | 1.20B |
| Net Income | 1.17B | 1.02B | 691.36M | 498.26M | -70.59M | 622.20M |
Balance Sheet | ||||||
| Total Assets | 14.61B | 13.62B | 11.53B | 10.34B | 8.80B | 8.60B |
| Cash, Cash Equivalents and Short-Term Investments | 363.13M | 460.75M | 415.86M | 361.16M | 73.78M | 465.83M |
| Total Debt | 3.49B | 3.65B | 3.11B | 2.81B | 2.54B | 2.63B |
| Total Liabilities | 6.18B | 5.77B | 5.13B | 4.98B | 4.19B | 3.89B |
| Stockholders Equity | 8.43B | 7.86B | 6.40B | 5.36B | 4.61B | 4.70B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -926.46M | -588.57M | -20.35M | -74.71M | 129.86M |
| Operating Cash Flow | 0 | 379.12M | 645.23M | 501.25M | 224.50M | 402.34M |
| Investing Cash Flow | 0 | -1.32B | -1.24B | -520.72M | -296.86M | -271.53M |
| Financing Cash Flow | 0 | 981.46M | 644.32M | 306.79M | -319.69M | -69.21M |
SMS Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSPHARMA, the sentiment is Neutral. The current price of 482.35 is below the 20-day moving average (MA) of 487.00, above the 50-day MA of 462.45, and above the 200-day MA of 400.73, indicating a neutral trend. The MACD of 11.17 indicates Positive momentum. The RSI at 50.55 is Neutral, neither overbought nor oversold. The STOCH value of 11.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SMSPHARMA.
SMS Pharmaceuticals Limited Peers Comparison
Overall Rating
IN:SMSPHARMA74Outperform
IN:MARKSANS69Neutral
IN:GLAND66Neutral
IN:SENORES63Neutral
IN:KOPRAN60.3Neutral
IN:NGLFINE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | INR 45.17B | 38.02 | ― | 0.08% | 12.96% | 32.16% | |
| 69Neutral | INR 135.56B | 24.19 | ― | 0.30% | 24.20% | 59.18% | |
| 66Neutral | INR 543.06B | 43.92 | ― | 0.61% | 21.90% | 56.28% | |
| 63Neutral | INR 51.14B | 36.50 | ― | ― | 39.71% | 53.21% | |
| 60Neutral | INR 12.88B | 32.81 | ― | 1.12% | 34.11% | 123.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | INR 17.21B | 26.88 | ― | 0.06% | 40.66% | 208.52% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SMSPHARMA | SMS Pharmaceuticals Limited | 482.35 | 210.78 | 77.62% | |
| IN:GLAND | Gland Pharma Ltd. | 3291.05 | 1513.45 | 85.14% | |
| IN:KOPRAN | Kopran Limited | 266.45 | 144.42 | 118.35% | |
| IN:MARKSANS | Marksans Pharma Limited | 299.15 | 110.62 | 58.68% | |
| IN:NGLFINE | NGL Fine-Chem Ltd. | 2785.85 | 1460.64 | 110.22% | |
| IN:SENORES | Senores Pharmaceuticals Ltd. | 1110.35 | 316.15 | 39.81% |
SMS Pharmaceuticals Limited Corporate Events
SMS Pharmaceuticals wins tax appeal; Rs 45.63 crore demand vacated
SMS Pharmaceuticals Limited has announced that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has allowed its appeal against an income tax assessment order for Assessment Year 2023-24. The appellate order under Section 250...
SMS Pharmaceuticals’ tax appeal dismissed; reduced demand upheld
SMS Pharmaceuticals Limited has disclosed that the Commissioner of Income Tax (Appeals), National Faceless Appeal Centre, has dismissed the company’s appeal against an earlier assessment order for the 2018-19 financial year. The case stems from a tax...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026
